Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial
Publication Type:
Journal Article
Authors:
G.T. Everson;
Hoefs, J.C.;
Seeff, L.B.;
Bonkovsky, H.L.;
Naishadham, D.;
Shiffman, M.L.;
Kahn, J.A.;
Lok, A.S.;
A M Di Bisceglie;
Lee, W.M.;
Dienstag, J.L.;
Ghany, M.G.;
Morishima, C.;
HALT-C trial groupSource:
Hepatology, Volume 44, Issue 6, p.1675-1684 (2006)
Keywords:
adverse effects,
Antiviral Agents,
Biopsy,
Colorado,
Disease,
drug therapy,
Drug Therapy,Combination,
Female,
Fibrosis,
Gastroenterology,
Genotype,
HCV,
hepatitis,
Hepatitis C,
Hepatitis C,Chronic,
Humans,
interferon,
Interferon Alfa-2a,
Interferon-alpha,
Liver,
Liver Cirrhosis,
Male,
Medicine,
Middle Aged,
Multicenter Studies,
pathology,
Patients,
peginterferon,
Platelet Count,
Polyethylene Glycols,
Proteins,
Recombinant Proteins,
Research,
Research Support,
Retreatment,
Ribavirin,
strategies,
sustained virologic response,
SVR,
therapeutic use,
therapy,
treatment,
Treatment Failure,
Treatment Outcome
